Glass House Brands (GLAS) Non-Current Deffered Revenue (2020 - 2021)
Glass House Brands (GLAS) posted quarterly Non-Current Deffered Revenue of $16.1 million for Q1 2021, little changed quarter-over-quarter from $16.1 million in Q4 2020.
Glass House Brands (GLAS) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Glass House Brands (GLAS) has reported Non-Current Deffered Revenue for 2 consecutive years, with $16.1 million the latest figure, recorded in Q1 2021.
- In Q1 2021, Non-Current Deffered Revenue changed N/A year-over-year to $16.1 million; the TTM figure through Mar 2021 stood at $16.1 million (changed N/A YoY), while the FY2020 annual figure was $16.1 million, changed N/A from the prior year.
- Non-Current Deffered Revenue steadied at $16.1 million in Q1 2021 per GLAS's latest filing, from $16.1 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $16.1 million in Q4 2020 and bottomed at $16.1 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Glass House Brands | 866.27 Mn | 847.71 Mn | 15.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 16.10 Mn |
| Dec 31, 2020 | 16.10 Mn |